GlassScriptPhysician profile
Terry N Brown
NPI 1124004759
$2,348.17
in general payments reported to CMS, 2019-2025
25 companies · $91.44 in 2025
The $91.44 reported for 2025 was less than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $855 · 2020: $127 · 2021: $461 · 2022: $531 · 2023: $105 · 2024: $178 · 2025: $91.44.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $374.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $374.23 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $361.50 | 2019-2025 | Mounjaro, Zepbound, Trulicity |
| Astrazeneca Pharmaceuticals LP | $308.48 | 2019-2022 | |
| Pfizer INC. | $300.55 | 2019-2024 | |
| Abbott Laboratories | $187.93 | 2021-2024 | Freestyle Libre 3 |
| Amarin Pharma, INC. | $187.52 | 2019-2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $179.95 | 2019-2022 | |
| Glaxosmithkline, LLC. | $149.33 | 2021-2023 | Shingrix, Trelegy Ellipta, Arexvy |
| Novartis Pharmaceuticals Corporation | $118.50 | 2019-2020 | |
| Abbvie INC. | $102.54 | 2021-2025 | Viberzi, Linzess |
| Astellas Pharma US INC | $75.20 | 2019-2024 | Veozah |
| Novo Nordisk INC | $63.52 | 2019-2022 | |
| Amgen INC. | $55.35 | 2019-2021 | |
| Janssen Pharmaceuticals, INC | $37.37 | 2019-2022 | |
| Kyowa Kirin, INC. | $26.10 | 2025 | |
| Madrigal Pharmaceuticals | $25.32 | 2024 | Resmetirom |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ultragenyx Pharmaceutical INC. | $23.29 | 2021 | |
| Mylan Specialty L.P. | $23.25 | 2021 | |
| Xeris Pharmaceuticals, INC. | $20.61 | 2021 | |
| Ferring Pharmaceuticals INC. | $17.64 | 2024 | Rebyota |
| Merck Sharp & Dohme LLC | $16.52 | 2024 | Gardasil, Gardasil 9, Capvaxive |
| Dexcom, INC. | $15.06 | 2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $14.26 | 2019 | |
| Exact Sciences Corporation | $14.14 | 2023 | Cologuard Collection Kit |
| E.R. Squibb & Sons, L.L.C. | $12.52 | 2019 | |
| Hologic Sales and Service, LLC | $11.72 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Terry Brown listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.